HIGHFDA DEVICE

Diagnostica Stago Recalls Asserachrom HPIA Kit Over False Negatives

Diagnostica Stago issued a recall for 438 Asserachrom HPIA kits on December 15, 2025. The kits, used to detect PF4 antibodies, may produce false negative results. The affected lot is 271288, distributed worldwide including multiple U.S. states.

Official notice
Diagnostica StagoHealth & Personal CareMedical DevicesReference Number: 00615. UDI: (01)03607450006155(11)240531(17)260531(10)271288(241)00615. Lot Number: 271288.

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DEVICE
Recall date
December 15, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
December 15, 2025
Hazard Level
HIGH
Brand
Diagnostica Stago
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Medical Devices; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Diagnostica Stago
Product type
Diagnostic Kit
Model numbers
Reference Number: 00615. UDI: (01)03607450006155(11)240531(17)260531(10)271288(241)00615. Lot Number: 271288.
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    December 15, 2025

  2. Reported by FDA DEVICE

    January 21, 2026

  3. RecallRadar source check

    January 28, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Potential for defect for Asserachrom HPIA lot 271288, which can affect every well in the impacted strip and produce negative results.

What You Should Do

Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Diagnostica Stago, Inc. or your healthcare provider for instructions. Notification method: E-Mail

About This Product

The Asserachrom HPIA kit is used for the qualitative detection of anti-heparin-platelet factor 4 antibodies in plasma or serum. It is primarily utilized in diagnosing heparin-induced thrombocytopenia, a serious condition that can occur after heparin treatment.

Why This Is Dangerous

The defect in the Asserachrom HPIA kit affects every well in the impacted strip, leading to potentially false negative results. This can result in undiagnosed cases of heparin-induced thrombocytopenia, posing severe health risks.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

The recall affects healthcare providers and patients relying on accurate diagnosis of heparin-induced thrombocytopenia. The potential for false negatives raises critical safety concerns.

Practical Guidance

How to identify if yours is affected

  1. Check the lot number of your Asserachrom HPIA kit.
  2. Verify if the lot number matches 271288.
  3. Confirm if you have received the kit from a healthcare provider or retailer.

Where to find product info

The lot number can typically be found on the packaging or the kit itself, often near the barcode or product details.

What timeline to expect

Expect processing for refunds or replacements to take approximately 4-6 weeks.

If the manufacturer is unresponsive

  • Contact your healthcare provider for further assistance.
  • Follow up with Diagnostica Stago via email to inquire about your recall status.

How to prevent similar issues

  • Always check for recalls on medical devices before use.
  • Consult your healthcare provider for alternatives if a product is recalled.
  • Be aware of the symptoms of heparin-induced thrombocytopenia for timely diagnosis.

Documentation advice

Keep copies of any correspondence regarding the recall, as well as receipts and product details for your records.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

The Asserachrom HPIA kit, Model/Catalog Number 00615, is designed for the qualitative detection of anti-heparin-platelet factor 4 antibodies in plasma or serum. It was distributed widely, including to states such as California, New York, and Florida, as well as internationally.

Key Facts

  • Model/Catalog Number: 00615
  • Distributed worldwide, including U.S. and several countries
  • Potential for false negative results

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Details

Model Numbers
Reference Number: 00615. UDI: (01)03607450006155(11)240531(17)260531(10)271288(241)00615. Lot Number: 271288.
Affected States
ALL
Report Date
January 21, 2026
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

Taro Pharmaceuticals Withdraws Diclofenac Sodium Gel Over Viscosity Issues

Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.

BEEKEEPER'S NATURALS USA
Microbial Contamination
Read more
Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more